Ontology highlight
ABSTRACT:
SUBMITTER: Baeten D
PROVIDER: S-EPMC6104676 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Baeten Dominique D Østergaard Mikkel M Wei James Cheng-Chung JC Sieper Joachim J Järvinen Pentti P Tam Lai-Shan LS Salvarani Carlo C Kim Tae-Hwan TH Solinger Alan A Datsenko Yakov Y Pamulapati Chandrasena C Visvanathan Sudha S Hall David B DB Aslanyan Stella S Scholl Paul P Padula Steven J SJ
Annals of the rheumatic diseases 20180626 9
<h4>Objectives</h4>To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).<h4>Methods</h4>A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing Spondylitis Disease Activity Index score of ≥4), were randomised (1:1:1:1) to risankizumab (18 mg single dose, 90 mg or 180 mg at day 1 and weeks 8, 16 and 24) or placebo over a 24-week bl ...[more]